Adi Leiba
Research Subjects
Adi Leiba has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Avital Angel-Korman
Division of Nephrology and Hypertension, Samson Assuta Ashdod Hospital, Ashdod, Israel
4 shared publicationsVladimir Rapoport
Division of Nephrology and Hypertension, Samson Assuta Ashdod Hospital, Ashdod, Israel
3 shared publicationsZeev Katzir
Division of Nephrology and Hypertension, Samson Assuta Ashdod Hospital, Ashdod, Israel
3 shared publications- Avital Angel Korman
Joyce and Irving Goldman School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel
2 shared publications - Estela Derazne
Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
2 shared publications - Jeremy D. Kark
Hebrew University-Hadassah School of Public Health and Community Medicine, Ein Kerem, Jerusalem, Israel
2 shared publications
Latest Publications
- Open Access
- 25 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 173
Adrenalectomy as a Treatment Option for Primary Aldosteronism in the Era of Robotic-Assisted Surgeries—Is It Time to Use It More Often?
Objectives: To evaluate clinical and biochemical outcomes of robotic-assisted laparoscopic adrenalectomy in patients with primary aldosteronism (PA) due to small aldosterone-producing adenomas, with emphasis on blood pressure (BP) control, antihypertensive medication burden, hormonal normalization, and safety. Methods: We prospectively enrolled PA patients (aldosterone >10 ng/dL, renin complete success (BP partial success (improvement in BP control with reduced medication and/or partial biochemical improvement), and failure (persistent hypertension and abnormal hormone levels). Results: From 2019 to present, 18 patients (median age 53 years; 13 male) with a median adenoma size of 15 mm (IQR 10–19.8) underwent robotic adrenalectomy (12 left, 6 right). Three (16.7%) with bilateral imaging findings had adrenal vein sampling to confirm unilateral disease. At 6 months, complete clinical success was achieved in 10 (55.5%) patients, partial success in 7 (38.9%), and failure in 1 (5.6%). Biochemically, 12 achieved complete normalization, 3 achieved partial improvement, and 3 did not complete testing. Median operative time was 110 min (IQR 100–120); median hospital stay was 3 days (IQR 3–4). No intra- or postoperative complications, transfusions, infections, or readmissions occurred. Conclusions: Robotic adrenalectomy for small aldosterone-producing adenomas in PA is safe, with high rates of BP normalization and hormonal remission and significantly reduced antihypertensive medication burden.
- 25 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 173
Open AccessAdrenalectomy as a Treatment Option for Primary Aldosteronism in the Era of Robotic-Assisted Surgeries—Is It Time to Use It More Often?
Objectives: To evaluate clinical and biochemical outcomes of robotic-assisted laparoscopic adrenalectomy in patients with primary aldosteronism (PA) due to small aldosterone-producing adenomas, with emphasis on blood pressure (BP) control, antihypertensive medication burden, hormonal normalization, and safety. Methods: We prospectively enrolled PA patients (aldosterone >10 ng/dL, renin complete success (BP partial success (improvement in BP control with reduced medication and/or partial biochemical improvement), and failure (persistent hypertension and abnormal hormone levels). Results: From 2019 to present, 18 patients (median age 53 years; 13 male) with a median adenoma size of 15 mm (IQR 10–19.8) underwent robotic adrenalectomy (12 left, 6 right). Three (16.7%) with bilateral imaging findings had adrenal vein sampling to confirm unilateral disease. At 6 months, complete clinical success was achieved in 10 (55.5%) patients, partial success in 7 (38.9%), and failure in 1 (5.6%). Biochemically, 12 achieved complete normalization, 3 achieved partial improvement, and 3 did not complete testing. Median operative time was 110 min (IQR 100–120); median hospital stay was 3 days (IQR 3–4). No intra- or postoperative complications, transfusions, infections, or readmissions occurred. Conclusions: Robotic adrenalectomy for small aldosterone-producing adenomas in PA is safe, with high rates of BP normalization and hormonal remission and significantly reduced antihypertensive medication burden.
- 22 September 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 39 (11) , 777-783
Infection with COVID-19 does not increase blood pressure in patients with chronic kidney disease
The association between hypertension (HTN) and COVID-19 in patients with chronic kidney disease (CKD) has not been completely elucidated. We aimed to study the effect of COVID-19 on HTN severity in patients with CKD. Included in the analysis were all adults, insured by Maccabi Healthcare Services, a large-scale Health Maintenance Organization, who were registered as having CKD on 1.7.2023. Patients in the study group had a confirmed SARS-CoV-2 infection during the study period (2020–2022), whereas patients in the control group did not. The infection date was defined as T0 for the study group, whereas T0-f-COVID denotes a matched time point for controls. We compared the differences in blood pressure values between pre- and post- T0 in both groups. A group of 85,502 CKD patients with documented COVID-19, of which 43,875 patients had at least two blood pressure (BP) measurements documented, both prior to and after T0 (study group). The control group of 136,645 CKD patients had no documented COVID-19 cases, and 58,874 had similarly documented BP measurements. On average, there were six BP measurements during the study period in both groups. The average BP values in the study group decreased by 1 mmHg systolic and 0.6 mmHg diastolic following COVID-19 (P value 0.03 and 0.004, respectively). The difference in BP values in the control group was −0.8 mmHg and −0.6 mmHg for systolic and diastolic BP (p < 0.001 for both values). Contrary to previous studies, our data demonstrated that BP does not increase following COVID-19 in patients with CKD.
- 22 September 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 39 (11) , 777-783
Infection with COVID-19 does not increase blood pressure in patients with chronic kidney disease
The association between hypertension (HTN) and COVID-19 in patients with chronic kidney disease (CKD) has not been completely elucidated. We aimed to study the effect of COVID-19 on HTN severity in patients with CKD. Included in the analysis were all adults, insured by Maccabi Healthcare Services, a large-scale Health Maintenance Organization, who were registered as having CKD on 1.7.2023. Patients in the study group had a confirmed SARS-CoV-2 infection during the study period (2020–2022), whereas patients in the control group did not. The infection date was defined as T0 for the study group, whereas T0-f-COVID denotes a matched time point for controls. We compared the differences in blood pressure values between pre- and post- T0 in both groups. A group of 85,502 CKD patients with documented COVID-19, of which 43,875 patients had at least two blood pressure (BP) measurements documented, both prior to and after T0 (study group). The control group of 136,645 CKD patients had no documented COVID-19 cases, and 58,874 had similarly documented BP measurements. On average, there were six BP measurements during the study period in both groups. The average BP values in the study group decreased by 1 mmHg systolic and 0.6 mmHg diastolic following COVID-19 (P value 0.03 and 0.004, respectively). The difference in BP values in the control group was −0.8 mmHg and −0.6 mmHg for systolic and diastolic BP (p < 0.001 for both values). Contrary to previous studies, our data demonstrated that BP does not increase following COVID-19 in patients with CKD.
- 28 March 2025
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 26
An unusual case of hypertension: take it with less than a grain of salt – a case report
The Yanomamo Indians live in the tropical equatorial rain forests of northern Brazil and southern Venezuela. They essentially eat a salt free diet. As such, they have been demonstrated to have minimal 24 h urine sodium excretion, markedly elevated serum renin and aldosterone levels, and low to normal blood pressure (BP) throughout their lives. We present an unusual case of a 75-year-old woman, with chronic kidney disease (CKD), stage 1 hypertension (HTN), and a partial colectomy who maintained a strict low salt diet while using a significant amount of a stimulant laxative (bisacodyl) on a daily basis.
- 28 March 2025
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 26
An unusual case of hypertension: take it with less than a grain of salt – a case report
The Yanomamo Indians live in the tropical equatorial rain forests of northern Brazil and southern Venezuela. They essentially eat a salt free diet. As such, they have been demonstrated to have minimal 24 h urine sodium excretion, markedly elevated serum renin and aldosterone levels, and low to normal blood pressure (BP) throughout their lives. We present an unusual case of a 75-year-old woman, with chronic kidney disease (CKD), stage 1 hypertension (HTN), and a partial colectomy who maintained a strict low salt diet while using a significant amount of a stimulant laxative (bisacodyl) on a daily basis.
- Open Access
- 13 February 2024
- Published by Springer Nature in Research Square
Unsatisfactory screening rates for Primary Aldosteronism in high risk patients
The Endocrine Society (ES) guidelines recommend screening for primary aldosteronism (PA) in high risk hypertensive patients presenting with at least one of seven criteria (resistant HTN, hypokalemia, adrenal nodule etc.). Although guidelines are clear and screening is simple, compliance rates among clinicians are extremely low. This results in underdiagnosis of early disease, leading to cadiovasculaer complications and extra-burden of advanced chronic kidney disease. We aimed to evaluate the screening rates in the Nephrology and Hypertension clinics at Assuta Ashdod University Hospital, Israel. Data on adult hypertensive patients was retrieved during January 2018 to December 2020. Included in the study were hypertensive patients who had at least one of the ES criteria for PA screening. Of all suitable patients, we compared those who were screened for PA to patients who were not screened. Univariate and multivariate cox regression analysis were used for comparison between groups. Of 661 patients with HTN, 218 patients (33%) met the ES guidelines for PA screening. Forty-six of them (21.1%), were referred for screening. Advanced age and male gender were associated with lower screening referral rates. Odds ratio for age was 0.945 for every year (95% CI 0.915-0.975). There was a trend towards decreased referral rate in advanced kidney disease. A 21% screening rate, suggests that many cases of PA are likely missed, more often in older patients.We therefore advocate for PA screening of all hypertensive patients, especially elderly patients with CKD, in whom clinicians’ awareness is low but the absolute risk is high.
- 13 February 2024
- Published by Springer Nature in Research Square
Open AccessUnsatisfactory screening rates for Primary Aldosteronism in high risk patients
The Endocrine Society (ES) guidelines recommend screening for primary aldosteronism (PA) in high risk hypertensive patients presenting with at least one of seven criteria (resistant HTN, hypokalemia, adrenal nodule etc.). Although guidelines are clear and screening is simple, compliance rates among clinicians are extremely low. This results in underdiagnosis of early disease, leading to cadiovasculaer complications and extra-burden of advanced chronic kidney disease. We aimed to evaluate the screening rates in the Nephrology and Hypertension clinics at Assuta Ashdod University Hospital, Israel. Data on adult hypertensive patients was retrieved during January 2018 to December 2020. Included in the study were hypertensive patients who had at least one of the ES criteria for PA screening. Of all suitable patients, we compared those who were screened for PA to patients who were not screened. Univariate and multivariate cox regression analysis were used for comparison between groups. Of 661 patients with HTN, 218 patients (33%) met the ES guidelines for PA screening. Forty-six of them (21.1%), were referred for screening. Advanced age and male gender were associated with lower screening referral rates. Odds ratio for age was 0.945 for every year (95% CI 0.915-0.975). There was a trend towards decreased referral rate in advanced kidney disease. A 21% screening rate, suggests that many cases of PA are likely missed, more often in older patients.We therefore advocate for PA screening of all hypertensive patients, especially elderly patients with CKD, in whom clinicians’ awareness is low but the absolute risk is high.
- Open Access
- 19 June 2023
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 29 (1) , 31-34
Comparison of blood pressure measurements on the bare and sleeved arms – what does it uncover?
Accurate office blood pressure (BP) measurement remains crucial in diagnosing and managing hypertension. In this study, we aimed to compare BP measurements done over a bare arm versus a sleeved arm, while controlling all other possible sources of variance. We collected BP measurements of 100 hypertensive patients visiting a nephrology and hypertension clinic between January 2019 and December 2023. Measurements were taken by a single operator and according to the updated guidelines. BP measurements were performed first with one arm bare, and the other arm sleeved, with measurements taken simultaneously. Then, measurements were again taken simultaneously after exposing the arm which was first sleeved, and dressing the arm which was bare at first. A nonparametric Wilcoxon test was performed to compare each patient’s measurements on each arm. No statistically significant differences were found between the sleeved and the bare arm measurements, with one exception of SBP measured on the left arm (slightly lower SBP on the bare arm). While looking at the absolute value of differences, the median difference was impressive with a 7–8 mmHg systolic difference and 5.5 mmHg diastolic difference. Our study revealed a robust and unpredicted effect of clothing on BP; in some patients, BP was increased while in others decreased. Therefore, we believe there is importance in measuring BP on bare skin, regardless of clothing or sleeve type.
- 19 June 2023
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 29 (1) , 31-34
Open AccessComparison of blood pressure measurements on the bare and sleeved arms – what does it uncover?
Accurate office blood pressure (BP) measurement remains crucial in diagnosing and managing hypertension. In this study, we aimed to compare BP measurements done over a bare arm versus a sleeved arm, while controlling all other possible sources of variance. We collected BP measurements of 100 hypertensive patients visiting a nephrology and hypertension clinic between January 2019 and December 2023. Measurements were taken by a single operator and according to the updated guidelines. BP measurements were performed first with one arm bare, and the other arm sleeved, with measurements taken simultaneously. Then, measurements were again taken simultaneously after exposing the arm which was first sleeved, and dressing the arm which was bare at first. A nonparametric Wilcoxon test was performed to compare each patient’s measurements on each arm. No statistically significant differences were found between the sleeved and the bare arm measurements, with one exception of SBP measured on the left arm (slightly lower SBP on the bare arm). While looking at the absolute value of differences, the median difference was impressive with a 7–8 mmHg systolic difference and 5.5 mmHg diastolic difference. Our study revealed a robust and unpredicted effect of clothing on BP; in some patients, BP was increased while in others decreased. Therefore, we believe there is importance in measuring BP on bare skin, regardless of clothing or sleeve type.
- Open Access
- 6 June 2023
- Published by Springer Nature in Artery Research
- Vol. 29 (3) , 73-78
Patients with CKD Secondary to Glomerular Disorders have Lower Arterial Stiffness, as Compared to Hypertensive and Diabetic CKD
Background: Chronic kidney disease (CKD) manifested as reduced GFR and/or albuminuria, has been known to accelerate arterial stiffness and early vascular aging (EVA). Diabetes, hypertension, and glomerular disorders are the leading causes of CKD and renal failure. The question which etiology contributes more to this vascular phenomenon-hypertensive and diabetic CKD or CKD secondary to immune-mediated glomerulonephritis—remained unclear. Objective: To compare pulse wave velocity (PWV), a marker of arterial stiffness, between CKD patients of different etiologies: hypertensive and diabetic nephrosclerosis. vs. CKD secondary to glomerular disorders. Methods: Clinical data were collected on 56 patients followed at the Nephrology and Hypertension Institute in Samson Assuta Ashdod University Hospital. All patients had at least one visit at our Nephrology clinics prior to recruitment. All patients with a glomerular disorder had a clinical-pathological diagnosis based on a recent kidney biopsy. Pulse wave velocity (PWV) was measured using a validated Sphygmocor XCEL® device. Univariate and multivariate analyses were performed to compare PWV between hypertensive/diabetic CKD and CKD secondary to glomerular disorders. Results: PWV was significantly higher in the hypertensive/diabetic CKD group, compared to the CKD-GN group, with an average of. 12.2 m/s vs 8.3 m/s, respectively (p < 0.001). In a multivariate linear regression model, having CKD secondary to glomerulonephritis was associated with a significantly lower PWV (B = − 3.262, p < 0.001), compared with CKD secondary to hypertension and diabetes, with adjustment of age, creatinine, and comorbidities. Conclusion: CKD Patients secondary to glomerulonephritis, have lower PWV when compared to CKD patients with diabetes and/or hypertension, even after adjusting for age, renal function, and the presence of comorbidities. It is intriguing to further study the possible protective role of immunosuppression on the arterial properties of CKD patients.
- 6 June 2023
- Published by Springer Nature in Artery Research
- Vol. 29 (3) , 73-78
Open AccessPatients with CKD Secondary to Glomerular Disorders have Lower Arterial Stiffness, as Compared to Hypertensive and Diabetic CKD
Background: Chronic kidney disease (CKD) manifested as reduced GFR and/or albuminuria, has been known to accelerate arterial stiffness and early vascular aging (EVA). Diabetes, hypertension, and glomerular disorders are the leading causes of CKD and renal failure. The question which etiology contributes more to this vascular phenomenon-hypertensive and diabetic CKD or CKD secondary to immune-mediated glomerulonephritis—remained unclear. Objective: To compare pulse wave velocity (PWV), a marker of arterial stiffness, between CKD patients of different etiologies: hypertensive and diabetic nephrosclerosis. vs. CKD secondary to glomerular disorders. Methods: Clinical data were collected on 56 patients followed at the Nephrology and Hypertension Institute in Samson Assuta Ashdod University Hospital. All patients had at least one visit at our Nephrology clinics prior to recruitment. All patients with a glomerular disorder had a clinical-pathological diagnosis based on a recent kidney biopsy. Pulse wave velocity (PWV) was measured using a validated Sphygmocor XCEL® device. Univariate and multivariate analyses were performed to compare PWV between hypertensive/diabetic CKD and CKD secondary to glomerular disorders. Results: PWV was significantly higher in the hypertensive/diabetic CKD group, compared to the CKD-GN group, with an average of. 12.2 m/s vs 8.3 m/s, respectively (p < 0.001). In a multivariate linear regression model, having CKD secondary to glomerulonephritis was associated with a significantly lower PWV (B = − 3.262, p < 0.001), compared with CKD secondary to hypertension and diabetes, with adjustment of age, creatinine, and comorbidities. Conclusion: CKD Patients secondary to glomerulonephritis, have lower PWV when compared to CKD patients with diabetes and/or hypertension, even after adjusting for age, renal function, and the presence of comorbidities. It is intriguing to further study the possible protective role of immunosuppression on the arterial properties of CKD patients.
- Open Access
- 24 August 2022
- Published by Taylor & Francis in Renal Failure
- Vol. 44 (1) , 1499-1501
G-CSF-induced ANCA associated glomerulonephritis in the presence of silent membranous “full house nephropathy” in an altruistic bone marrow donor
Dear Editor,Neupogen (Filgrastim) is a recombinant human granulocyte colony stimulating factor (G-CSF) commonly used to stimulate progenitor cell collection for the purpose of bone marrow transplan...
- 24 August 2022
- Published by Taylor & Francis in Renal Failure
- Vol. 44 (1) , 1499-1501
Open AccessG-CSF-induced ANCA associated glomerulonephritis in the presence of silent membranous “full house nephropathy” in an altruistic bone marrow donor
Dear Editor,Neupogen (Filgrastim) is a recombinant human granulocyte colony stimulating factor (G-CSF) commonly used to stimulate progenitor cell collection for the purpose of bone marrow transplan...
- 23 August 2022
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 37 (7) , 542-547
Resistant hypertension is associated with an increased cardiovascular risk compared to patients controlled on a similar multi-drug regimen
The long-term risk associated with resistant hypertension compared to other phenotypes of hypertension is still unclear. We aimed to assess cardiovascular and renal outcomes over 10 years of follow-up of patients with uncontrolled resistant hypertension (uRH) compared to a similarly treated (≥ 3 medication classes including a diuretic) and adherent group whose blood pressure is under control. This retrospective cohort study utilized the computerized database of Maccabi Healthcare Services, a state-mandated health provider covering 25% of the Israeli population. Clinical outcomes were assessed using Cox regression multivariable analyses. A total of 1487 patients (50% males, mean age at baseline = 68.3 ± 10.4 years) were included in the uRH cohort and 1343 patients (50% males, 66.2 ± 10.6 years) in the controlled hypertension reference group (Controlled hypertension on multi drug regimen- CH-MDR). After adjusting for age, sex, BMI and patients’ comorbidities, uRH was associated with a Hazard Ratio of 1.35 (95% CI: 1.08–1.69) for incidence of ischemic heart disease, 1.51 (1.06–2.16) for secondary cardiovascular events, and 1.36 (1.00–1.86) for risk of stroke or transient ischemic attack compared to the reference group. Patients with uRH were found to have more hospitalization days (mean, 4.2 vs. 3 days per year, p < 0.001), and more emergency room visits (83.3% vs. 77%, p < 0.001). Overall, uRH was associated with a 19% (95% CI 11% to 29%) increase in direct healthcare expenditures during the first year of follow-up. uRH is associated with a substantial increased risk of both cardiovascular and cerebrovascular events, when compared to similarly treated hypertensive patients whose blood pressure is under control.
- 23 August 2022
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 37 (7) , 542-547
Resistant hypertension is associated with an increased cardiovascular risk compared to patients controlled on a similar multi-drug regimen
The long-term risk associated with resistant hypertension compared to other phenotypes of hypertension is still unclear. We aimed to assess cardiovascular and renal outcomes over 10 years of follow-up of patients with uncontrolled resistant hypertension (uRH) compared to a similarly treated (≥ 3 medication classes including a diuretic) and adherent group whose blood pressure is under control. This retrospective cohort study utilized the computerized database of Maccabi Healthcare Services, a state-mandated health provider covering 25% of the Israeli population. Clinical outcomes were assessed using Cox regression multivariable analyses. A total of 1487 patients (50% males, mean age at baseline = 68.3 ± 10.4 years) were included in the uRH cohort and 1343 patients (50% males, 66.2 ± 10.6 years) in the controlled hypertension reference group (Controlled hypertension on multi drug regimen- CH-MDR). After adjusting for age, sex, BMI and patients’ comorbidities, uRH was associated with a Hazard Ratio of 1.35 (95% CI: 1.08–1.69) for incidence of ischemic heart disease, 1.51 (1.06–2.16) for secondary cardiovascular events, and 1.36 (1.00–1.86) for risk of stroke or transient ischemic attack compared to the reference group. Patients with uRH were found to have more hospitalization days (mean, 4.2 vs. 3 days per year, p < 0.001), and more emergency room visits (83.3% vs. 77%, p < 0.001). Overall, uRH was associated with a 19% (95% CI 11% to 29%) increase in direct healthcare expenditures during the first year of follow-up. uRH is associated with a substantial increased risk of both cardiovascular and cerebrovascular events, when compared to similarly treated hypertensive patients whose blood pressure is under control.
- 1 April 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 86, 79-85
Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study
- 1 April 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 86, 79-85
Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study
- Open Access
- 5 June 2018
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 1-10
Sex-specific associations between adolescent categories of BMI with cardiovascular and non-cardiovascular mortality in midlife
Most studies linking long-term consequences of adolescent underweight and obesity are limited to men. To assess the sex-specific association of adolescent BMI with cardiovascular- and non-cardiovascular-related mortality in young adulthood and midlife. A nationwide cohort. 927,868 women, 1,366,271 men. Medical examination data at age 17, including BMI, were linked to the national death registry. Death attributed to cardiovascular (CVD) and non-CVD causes. During 17,346,230 women-years and 28,367,431 men-years of follow-up, there were 451 and 3208 CVD deaths, respectively, and 6235 and 22,223 non-CVD deaths, respectively. Compared to low-normal BMI (18.5–22.0 kg/m2), underweight women had a lower adjusted risk for CVD mortality (Cox hazard ratio (HR) = 0.68; 95% CI 0.46–0.98) in contrast to underweight men (HR = 0.99; 0.88–1.13). The latter were at higher risk for non-CVD mortality (HR = 1.04; 1.00–1.09), unlike underweight women (HR = 1.01; 0.93–1.10). Findings, which persisted when the study sample was limited to those with unimpaired health, were accentuated for the obese with ≥ 30 years follow-up. Both sexes exhibited similarly higher risk estimates already in the high-normal BMI range (22.0 ≤ BMI < 25.0 kg/m2) with overall no interaction between sex and BMI (p = 0.62). Adjusted spline models suggested lower BMI values for minimal mortality risk among women (16.8 and 18.2 kg/m2) than men (18.8 and 20.0 kg/m2), for CVD and non-CVD death, respectively. Underweight adolescent females have favorable cardiovascular outcomes in adulthood. Otherwise the risk patterns were similar between the sexes. The optimal BMI value for women and men with respect to future CVD outcomes is within or below the currently accepted low-normal BMI range.
- 5 June 2018
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 1-10
Open AccessSex-specific associations between adolescent categories of BMI with cardiovascular and non-cardiovascular mortality in midlife
Most studies linking long-term consequences of adolescent underweight and obesity are limited to men. To assess the sex-specific association of adolescent BMI with cardiovascular- and non-cardiovascular-related mortality in young adulthood and midlife. A nationwide cohort. 927,868 women, 1,366,271 men. Medical examination data at age 17, including BMI, were linked to the national death registry. Death attributed to cardiovascular (CVD) and non-CVD causes. During 17,346,230 women-years and 28,367,431 men-years of follow-up, there were 451 and 3208 CVD deaths, respectively, and 6235 and 22,223 non-CVD deaths, respectively. Compared to low-normal BMI (18.5–22.0 kg/m2), underweight women had a lower adjusted risk for CVD mortality (Cox hazard ratio (HR) = 0.68; 95% CI 0.46–0.98) in contrast to underweight men (HR = 0.99; 0.88–1.13). The latter were at higher risk for non-CVD mortality (HR = 1.04; 1.00–1.09), unlike underweight women (HR = 1.01; 0.93–1.10). Findings, which persisted when the study sample was limited to those with unimpaired health, were accentuated for the obese with ≥ 30 years follow-up. Both sexes exhibited similarly higher risk estimates already in the high-normal BMI range (22.0 ≤ BMI < 25.0 kg/m2) with overall no interaction between sex and BMI (p = 0.62). Adjusted spline models suggested lower BMI values for minimal mortality risk among women (16.8 and 18.2 kg/m2) than men (18.8 and 20.0 kg/m2), for CVD and non-CVD death, respectively. Underweight adolescent females have favorable cardiovascular outcomes in adulthood. Otherwise the risk patterns were similar between the sexes. The optimal BMI value for women and men with respect to future CVD outcomes is within or below the currently accepted low-normal BMI range.